Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVAMP: Resveratrol for vascular cognitive impairment in asymptomatic carotid stenosis
jRCTs051230013Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in vascular cognitive disorder (VCD), carotid atheroma (CAS) and Carotid artery occlusion (CAO) comparing Resveratrol with Placebo (2 arms). Primary endpoint: ADAS-Cog 13 change. Started Apr 2023; status: active, not recruiting.
02
Drugs
resveratrol
03
Conditions
vascular cognitive disorder (VCD)carotid atheroma (CAS)Carotid artery occlusion (CAO)
Beyond the preview
Go deeper on jRCTs051230013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230013.